Provided by Tiger Trade Technology Pte. Ltd.

NRX Pharmaceuticals Inc.

2.85
-0.0700-2.40%
Post-market: 2.900.0500+1.75%19:44 EDT
Volume:625.98K
Turnover:1.80M
Market Cap:123.39M
PE:-3.68
High:3.00
Open:2.94
Low:2.83
Close:2.92
52wk High:5.06
52wk Low:1.62
Shares:43.30M
Float Shares:37.42M
Volume Ratio:0.80
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7754
EPS(LYR):-1.3374
ROE:-682.61%
ROA:-63.99%
PB:-725.84
PE(LYR):-2.13

Loading ...

Kadima Neuropsychiatry Institute Files Suit Against NRX Pharmaceuticals (nasdaq: Nrxp), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition

THOMSON REUTERS
·
Jun 25

Kadima Neuropsychiatry Institute: Lawsuit Seeks Specific Performance in Court Order Compelling Defendants to Close Deal on Terms in Executed Agreement

THOMSON REUTERS
·
Jun 25

Kadima Neuropsychiatry Institute: Complaint Alleges NRX Warranted it Had Funds to Close While Concealing it Lacked Committed Financing for Deal

THOMSON REUTERS
·
Jun 25

Kadima Neuropsychiatry Institute Sues Nrx Pharma over Alleged Breach, Misrepresentation in Acquisition Deal

Reuters
·
Jun 25

HOPE Therapeutics treats first patient using Zeta TMS Navigation System

Reuters
·
Jun 23

Zeta Surgical® Announces Successful Treatment of First Patient With Zeta Tms Navigation System at Hope Therapeutics

THOMSON REUTERS
·
Jun 23

Thomas Shrader Reiterates Buy on NRXP, Maintains $25 Price Target on NRX-100/101 FDA and RWE-Driven Upside

TIPRANKS
·
Jun 23

NRx Pharma says FDA grants expanded access protocol for NRX-101 depression treatment

Reuters
·
Jun 22

NRX Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-Based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

THOMSON REUTERS
·
Jun 22

NRX Pharmaceuticals - to Charge Only Shipping and Data Costs for NRX-101 Under Protocol

THOMSON REUTERS
·
Jun 22

NRX Pharmaceuticals - Initiates Pivotal Trial of NRX-101 for Tms Augmentation

THOMSON REUTERS
·
Jun 22

NRx notes real-world study showing IV ketamine beats nasal esketamine on depression remission, response rates

Reuters
·
Jun 05

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

GlobeNewswire
·
Jun 05

NRx Pharmaceuticals closes USD 22.3 million follow-on stock offering at USD 3.5 a share

Reuters
·
Jun 05

NRX Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option

THOMSON REUTERS
·
Jun 05

BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway

Reuters
·
Jun 03

BUZZ-U.S. STOCKS ON THE MOVE-Ollie's Bargain Outlet Holdings, Steel Dynamics

Reuters
·
Jun 03

BUZZ-NRx Pharma dives on deep-discounted share offering

Reuters
·
Jun 03

NRx Pharmaceuticals prices 5,714,286-share follow-on at $3.5 per share

Reuters
·
Jun 03

NRX Pharmaceuticals - Prices Public Offering of 5.71 Mln Shares at $3.5 per Share

THOMSON REUTERS
·
Jun 03